Yarrow Bioscience files investor presentation and updated business description
Yarrow Bioscience filed an 8-K on September 10, 2026, furnishing a September 2026 investor presentation and an update to the Business section of its 2025 Form 10-K to reflect its merger with Yarrow Bioscience Operating Company Corp. The company states the revisions have no effect on previously reported results, financial position, or cash flows, and the presentation says the company's cash resources are expected to fund operations into 2028.
Key points
- Investor presentation dated September 2026 made available on September 10, 2026 (Exhibit 99.1)
- Business update reflects the merger with Yarrow Bioscience Operating Company Corp. (formerly Yarrow Bioscience, Inc.); company states no effect on previously reported results
- Presentation cites $200 million raised to date and cash runway expected into 2028
- Phase 2a readout for YB-101 in Graves' disease anticipated in 2H 2027
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.